dopamine receptor D3 |
LACIDIPINE |
Dopamine D3 |
77% |
6.17uM |
2.096uM |
View
|
adrenergic receptor, alpha 2b |
RALOXIFENE |
Adrenergic alpha2C |
77% |
.738uM |
.107uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
RALOXIFENE |
Adrenergic alpha2C |
77% |
.738uM |
.107uM |
View
|
adrenergic receptor, beta 3 |
CLOMIPHENE |
Adrenergic beta3 |
77% |
5.673uM |
4.254uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
VENLAFAXINE |
Adrenergic, Norepinephrine Transporter |
77% |
2.708uM |
2.685uM |
View
|
cholinergic receptor, muscarinic 2 |
CLOMIPHENE |
Muscarinic M2 |
77% |
3.628uM |
1.29uM |
View
|
Sigma-2 Receptor |
DROPERIDOL |
Sigma2 |
77% |
3.283uM |
2.02uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
DIPHENHYDRAMINE |
Serotonin 5-HT2B |
77% |
1.118uM |
.711uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
DIPHENHYDRAMINE |
Adrenergic, Norepinephrine Transporter |
77% |
3.542uM |
3.513uM |
View
|
Cytochrom P450-1A2 monooxygenase |
DISULFIRAM |
CYP450-1A2 Inhibition |
77% |
4uM |
NoneNone |
View
|
adrenergic receptor, alpha 1d (Non-specific probe) |
TAMOXIFEN |
Adrenergic alpha1D |
77% |
4.982uM |
2.449uM |
View
|
adrenergic receptor, alpha 2a |
ERGONOVINE |
Imidazoline I2, Central |
77% |
1.843uM |
1.228uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
ERGONOVINE |
Imidazoline I2, Central |
77% |
1.843uM |
1.228uM |
View
|
dopamine receptor D1A |
ERGONOVINE |
Dopamine D1 |
77% |
5.901uM |
2.95uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
CLEMASTINE |
Adrenergic, Norepinephrine Transporter |
77% |
3.086uM |
3.06uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
CLOZAPINE |
Adrenergic, Norepinephrine Transporter |
77% |
1.47uM |
1.458uM |
View
|
leukotriene B4 receptor 2 |
BENZOTHIAZYL DISULFIDE |
Leukotriene B4 |
77% |
5.1uM |
1.3uM |
View
|
leukotriene B4 receptor |
BENZOTHIAZYL DISULFIDE |
Leukotriene B4 |
77% |
5.1uM |
1.3uM |
View
|
leukotriene B4 receptor |
BENZOTHIAZYL DISULFIDE |
Leukotriene B4 |
77% |
5.1uM |
1.3uM |
View
|
leukotriene B4 receptor 2 |
BENZOTHIAZYL DISULFIDE |
Leukotriene B4 |
77% |
5.1uM |
1.3uM |
View
|
cholinergic receptor, muscarinic 1 |
FLUOXETINE |
Muscarinic M1 |
77% |
3.203uM |
.771uM |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2D |
DEXTROMETHORPHAN |
Glutamate, NMDA, Phencyclidine |
77% |
2.415uM |
1.636uM |
View
|
glutamate receptor, ionotropic, NMDA2C |
DEXTROMETHORPHAN |
Glutamate, NMDA, Phencyclidine |
77% |
2.415uM |
1.636uM |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2B |
DEXTROMETHORPHAN |
Glutamate, NMDA, Phencyclidine |
77% |
2.415uM |
1.636uM |
View
|
glutamate receptor, ionotropic, N-methyl D-aspartate 2A |
DEXTROMETHORPHAN |
Glutamate, NMDA, Phencyclidine |
77% |
2.415uM |
1.636uM |
View
|
N-methyl-D-aspartate receptor 1 (Grin1) gene, exons 1 through 6 and partial cds; alternatively spliced (Rn.) |
DEXTROMETHORPHAN |
Glutamate, NMDA, Phencyclidine |
77% |
2.415uM |
1.636uM |
View
|
glutamate receptor, ionotropic, N-methyl-D-aspartate 3B |
DEXTROMETHORPHAN |
Glutamate, NMDA, Phencyclidine |
77% |
2.415uM |
1.636uM |
View
|
solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
IPRIFLAVONE |
Adrenergic, Norepinephrine Transporter |
77% |
2.5125uM |
2.4917uM |
View
|
lymphocyte protein tyrosine kinase (mapped) |
S(-)-CARBIDOPA |
Protein Tyrosine Kinase, Lck |
77% |
6.795uM |
NoneNone |
View
|
adrenergic receptor, alpha 2a |
TRAZODONE |
Imidazoline I2, Central |
77% |
2.891uM |
1.927uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
TRAZODONE |
Imidazoline I2, Central |
77% |
2.891uM |
1.927uM |
View
|
5-hydroxytryptamine (serotonin) receptor 1B |
TRAZODONE |
Serotonin 5-HT1B |
77% |
1.356uM |
.83uM |
View
|
cholinergic receptor, muscarinic 3 |
GENTIAN VIOLET |
Muscarinic M3 |
77% |
4.33uM |
.918uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type X, alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type IV, beta |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type III, alpha |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
sodium channel, voltage-gated, type II, beta |
CITALOPRAM |
Sodium Channel, Site 2 |
77% |
2.641uM |
2.409uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
DIPHENHYDRAMINE |
Calcium Channel Type L, Phenylalkylamine |
76% |
7.28uM |
7.078uM |
View
|
5-hydroxytryptamine receptor 6 |
DISULFIRAM |
Serotonin 5-HT6 |
76% |
16.001uM |
7.429uM |
View
|
Sigma-2 Receptor |
TRIHEXYPHENIDYL |
Sigma2 |
76% |
3.122uM |
1.921uM |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
ATPase, Na+/K+ transporting, beta 3 polypeptide |
CLADRIBINE |
ATPase, Na+/K+ |
13% |
NoneNone |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
METHYSERGIDE |
Calcium Channel Type L, Benzothiazepine |
76% |
3.559uM |
3.164uM |
View
|
adrenergic receptor, alpha 2a |
LEAD (II) ACETATE |
Adrenergic alpha2A |
76% |
3.597uM |
1.349uM |
View
|
5-hydroxytryptamine (serotonin) receptor 2A |
PROPRANOLOL |
Serotonin 5-HT2A |
76% |
1.466uM |
.419uM |
View
|
adrenergic receptor, alpha 2b |
QUINACRINE |
Adrenergic alpha2B |
76% |
1.825uM |
.833uM |
View
|
cholinergic receptor, muscarinic 5 |
QUINACRINE |
Muscarinic M5 |
76% |
3.736uM |
2.684uM |
View
|
histamine receptor H 2 |
IMIQUIMOD |
Histamine H2 |
76% |
1.506uM |
1.481uM |
View
|
adrenergic receptor, alpha 2b |
SERTRALINE |
Adrenergic alpha2C |
76% |
4.477uM |
.6505uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
SERTRALINE |
Adrenergic alpha2C |
76% |
4.477uM |
.6505uM |
View
|
monoamine oxidase A |
SELEGILINE |
Monoamine Oxidase MAOA |
76% |
2.984uM |
NoneNone |
View
|
monoamine oxidase A |
SELEGILINE |
Monoamine Oxidase MAOA |
76% |
2.984uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 2B |
SERTRALINE |
Serotonin 5-HT2B |
76% |
3.3935uM |
2.1595uM |
View
|
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
NORGESTREL |
Serotonin Transporter |
76% |
1.119uM |
.595uM |
View
|
prostaglandin-endoperoxide synthase 2 |
NAPROXEN |
Cyclooxygenase COX-2 |
76% |
17.001uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
NAPROXEN |
Cyclooxygenase COX-2 |
76% |
17.001uM |
NoneNone |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 5 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 4 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 3 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 2 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, gamma subunit 1 |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, beta 4 subunit |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, beta 3 subunit |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, beta 2 subunit |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1S subunit |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
OXICONAZOLE |
Calcium Channel Type L, Phenylalkylamine |
76% |
2.7269uM |
2.6512uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
SIBUTRAMINE |
Calcium Channel Type L, Benzothiazepine |
75% |
.809uM |
.719uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
SIBUTRAMINE |
Calcium Channel Type L, Benzothiazepine |
75% |
.809uM |
.719uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
SIBUTRAMINE |
Calcium Channel Type L, Benzothiazepine |
75% |
.809uM |
.719uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
SIBUTRAMINE |
Calcium Channel Type L, Benzothiazepine |
75% |
.809uM |
.719uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
SIBUTRAMINE |
Calcium Channel Type L, Benzothiazepine |
75% |
.809uM |
.719uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
SIBUTRAMINE |
Calcium Channel Type L, Benzothiazepine |
75% |
.809uM |
.719uM |
View
|
adrenergic receptor, beta 3 |
CANDESARTAN |
Adrenergic beta3 |
75% |
4.3uM |
3.2uM |
View
|
Cytochrom P450-1A2 monooxygenase |
ARTEMISININ |
CYP450-1A2 Inhibition |
75% |
2uM |
NoneNone |
View
|
adrenergic receptor, alpha 2b |
DAPIPRAZOLE |
Adrenergic alpha2B |
75% |
1.153uM |
.526uM |
View
|
phosphodiesterase 4A, cAMP specific |
SB-203580 |
Phosphodiesterase PDE4 |
75% |
11.59uM |
NoneNone |
View
|
phosphodiesterase 4C, cAMP-specific |
SB-203580 |
Phosphodiesterase PDE4 |
75% |
11.59uM |
NoneNone |
View
|
phosphodiesterase 4D |
SB-203580 |
Phosphodiesterase PDE4 |
75% |
11.59uM |
NoneNone |
View
|
phosphodiesterase 4B, cAMP specific |
SB-203580 |
Phosphodiesterase PDE4 |
75% |
11.59uM |
NoneNone |
View
|
sodium channel, nonvoltage-gated 1 beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, nonvoltage-gated 1, gamma |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, nonvoltage-gated 1, delta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type X, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage gated, type VIII, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type IV, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type IV, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type III, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type II, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type II, alpha 2 |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type I, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type I, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type IV, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel associated protein 1 |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel associated protein 2 |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type III, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type I, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type III, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type XI, alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type I, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type 10, alpha polypeptide |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type IV, alpha polypeptide |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type V, alpha polypeptide |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, voltage-gated, type II, beta |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, nonvoltage-gated 1 alpha |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
sodium channel, nonvoltage-gated 1 gamma |
NISOLDIPINE |
Sodium Channel, Site 2 |
75% |
7.354uM |
6.709uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
CLOMIPHENE |
Calcium Channel Type L, Dihydropyridine |
75% |
1.62uM |
1.041uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
CLOMIPHENE |
Calcium Channel Type L, Dihydropyridine |
75% |
1.62uM |
1.041uM |
View
|
calcium channel, voltage-dependent, alpha 1F subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1D subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1C subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, beta 1 subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, L type, alpha 1E subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, N type, alpha 1B subunit |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
melanocortin 5 receptor |
SERTRALINE |
Melanocortin MC5 |
74% |
4.598uM |
4.3132uM |
View
|
calcium channel, voltage-dependent, gamma subunit 8 |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, gamma subunit 7 |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
calcium channel, voltage-dependent, gamma subunit 6 |
SERTRALINE |
Calcium Channel Type L, Benzothiazepine |
74% |
1.468uM |
1.3049uM |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, gamma 1 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, pi |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
AT hook, DNA binding motif, containing 1 (DBSS) |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, theta |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, gamma 2 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 6 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, alpha 2 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, alpha 1 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 2 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid (GABA-C) receptor, subunit rho 1 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid A receptor, delta |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 3 |
NORGESTREL |
GABAA, Benzodiazepine, Central |
74% |
2.359uM |
1.922uM |
View
|
prostaglandin-endoperoxide synthase 1 |
NIFLUMIC ACID |
Cyclooxygenase COX-1 |
74% |
1.064uM |
NoneNone |
View
|
prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) |
NIFLUMIC ACID |
Cyclooxygenase COX-1 |
74% |
1.064uM |
NoneNone |
View
|
adrenergic receptor, alpha 1d (Non-specific probe) |
OXYMETAZOLINE |
Adrenergic alpha1D |
74% |
2.844uM |
1.398uM |
View
|
adrenergic receptor, alpha 2a |
ORPHENADRINE |
Adrenergic alpha2A |
74% |
2.156uM |
.809uM |
View
|
adrenergic receptor, alpha 2a |
CADMIUM CHLORIDE |
Adrenergic alpha2A |
74% |
6.918uM |
2.594uM |
View
|
tachykinin receptor 2 |
CETYLPYRIDINIUM BROMIDE |
Tachykinin NK2 |
74% |
8.632uM |
2.877uM |
View
|
androgen receptor |
CLOBETASOL PROPIONATE |
Testosterone |
74% |
3.775uM |
2.517uM |
View
|
mitogen activated protein kinase 1 |
SULFASALAZINE |
Protein Serine/Threonine Kinase, ERK2 |
74% |
6.332uM |
NoneNone |
View
|
mitogen-activated protein kinase 1 |
SULFASALAZINE |
Protein Serine/Threonine Kinase, ERK2 |
74% |
6.332uM |
NoneNone |
View
|
5-hydroxytryptamine (serotonin) receptor 5B |
DROPERIDOL |
Serotonin 5-HT4 |
74% |
3.789uM |
.632uM |
View
|
5-hydroxytryptamine (serotonin) receptor 4 |
DROPERIDOL |
Serotonin 5-HT4 |
74% |
3.789uM |
.632uM |
View
|
phosphodiesterase 4C, cAMP-specific |
DIPYRIDAMOLE |
Phosphodiesterase PDE4 |
74% |
1.579uM |
NoneNone |
View
|
phosphodiesterase 4D |
DIPYRIDAMOLE |
Phosphodiesterase PDE4 |
74% |
1.579uM |
NoneNone |
View
|
phosphodiesterase 4B, cAMP specific |
DIPYRIDAMOLE |
Phosphodiesterase PDE4 |
74% |
1.579uM |
NoneNone |
View
|
chemokine (C-C motif) receptor 2 |
BENZOTHIAZYL DISULFIDE |
Chemokine CCR2B |
74% |
2.405uM |
.929uM |
View
|
5-hydroxytryptamine receptor 6 |
FLUOXETINE |
Serotonin 5-HT6 |
74% |
1.661uM |
.771uM |
View
|
adrenergic receptor, alpha 2a |
DOXEPIN |
Imidazoline I2, Central |
74% |
1.839uM |
1.226uM |
View
|
adrenergic receptor, alpha 2c (Non-specific probe) |
DOXEPIN |
Imidazoline I2, Central |
74% |
1.839uM |
1.226uM |
View
|
sodium channel, voltage-gated, type IV, beta |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel associated protein 1 |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel associated protein 2 |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel, voltage-gated, type III, beta |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel, voltage-gated, type I, alpha |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel, voltage-gated, type IX, alpha |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel, voltage-gated, type VII, alpha |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
amiloride-sensitive cation channel 5, intestinal |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel, voltage-gated, type III, beta |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|
sodium channel, voltage-gated, type VIII, alpha polypeptide |
DOXEPIN |
Sodium Channel, Site 2 |
74% |
2.542uM |
2.319uM |
View
|